Novan, Inc. is a late-stage pharmaceutical company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a pipeline of differentiated, first-in-class product candidates.  The Company's lead product candidate, SB204, a cosmetically elegant topical gel for the treatment of acne vulgaris, is expected to enter Phase 3 clinical testing in Q1 2016, with top line results anticipated in the 1H 2017.  SB206, a topical anti-viral for the treatment of external genital and perianal warts caused by human papillomavirus (HPV) is in Phase 2 clinical development, with top line results expected in 2H 2016.

Learn More about Novan

Close
Close